The DOI matches its Crossref record; 103 of the 107 references it cites were found in a registry or an index.
Senescence as a therapeutically relevant response to CDK4/6 inhibitors
Open accessAbstract
Cyclin-dependent kinases 4 and 6 (CDK4/6) phosphorylate and inhibit retinoblastoma (RB) family proteins. Hyperphosphorylated RB releases E2F transcription factors, activating a transcriptional program that initiates S phase. Due to the critical role that this pathway has in regulating cell cycle progression, inhibiting CDK4/6 is an attractive therapeutic strategy. Indeed, CDK4/6 inhibitors in combination with antiestrogens produce a significant benefit in patients with ER+/HER2- breast cancer. Clinical trials are currently investigating if the use of CDK4/6 inhibitors alone or in combination can be extended to other cancer types. Inhibition of CDK4/6 can result in different cell fates such as quiescence, senescence, or apoptosis. Senescence is a stress response that can be induced by stimuli that include oncogenic activation, chemotherapy, irradiation, and targeted therapies such as CDK4/6 inhibitors. Senescent cells undergo a stable cell cycle arrest and produce a bioactive secretome that remodels their microenvironment and engages the immune system. In this review, we analyze the therapeutic relevance of senescence induction by CDK4/6 inhibitors. We also discuss how different therapies, including checkpoint inhibitors and drugs targeting MEK or PI3K, can be used in combination with CDK4/6 inhibitors to reinforce or exploit senescence. Recently, a lot of effort has been put into identifying compounds that selectively kill senescent cells (termed senolytics). Thus, sequential treatment with senolytics might be an additional strategy to potentiate the antitumor effects of CDK4/6 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some targeted therapies, such as inhibitors of aurora kinase or CDK4/6 also trigger tumor senescence and show promise in treating a number of cancers (Wagner and Gil 2020).”
From Senescence and the SASP: many therapeutic avenues (2020) · cites this paper as Wagner and Gil 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
The serial cultivation of human diploid cell strains
Hayflick, L., & Moorhead, P. S. (1961) · Experimental Cell Research · doi:10.1016/0014-4827(61)90192-6 · Cited by 8,508
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Cellular Senescence: Defining a Path Forward
Gorgoulis, V., Adams, P. D., Alimonti, A., Bennett, D. C., Bischof, O., Bishop, C., Campisi, J., Collado, M., Evangelou, K., Ferbeyre, G., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.005 · Cited by 3,225
Self-citationAlpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Cited by
Sorted by citations
Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506
Senescence and the SASP: many therapeutic avenues
Birch, J., & Gil, J. (2020) · Genes & Development · doi:10.1101/gad.343129.120 · Cited by 1,177
Self-citationTherapy-Induced Senescence: Opportunities to Improve Anticancer Therapy
Prasanna, P. G. S., Citrin, D. E., Hildesheim, J., Ahmed, M. M., Venkatachalam, S., Riscuta, G., Xi, D., Zheng, G., van Deursen, J., Goronzy, J. J., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab064 · Cited by 359
Self-citationAdjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Gnant, M., Dueck, A. C., Frantal, S., Martin, M., Burstein, H. J., Greil, R., Fox, P., Wolff, A. C., Chan, A., Winer, E. P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02554 · Cited by 235
Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Chen, H.-A., Ho, Y.-J., Mezzadra, R., Adrover, J. M., Smolkin, R. M., Zhu, C., Woess, K., Bernstein, N., Schmitt, G., Fong, L. E., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0528 · Cited by 241
Cellular senescence and the tumour microenvironment
Takasugi, M., Yoshida, Y., & Ohtani, N. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13268 · Cited by 190
The role of cellular senescence and SASP in tumour microenvironment
Takasugi, M., Yoshida, Y., Hara, E., & Ohtani, N. (2023) · The FEBS Journal · doi:10.1111/febs.16381 · Cited by 144
Senescence and the tumor-immune landscape: Implications for cancer immunotherapy
Chibaya, L., Snyder, J. T., & Ruscetti, M. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.005 · Cited by 146
CDK4/6 inhibitors induce replication stress to cause long‐term cell cycle withdrawal
Crozier, L., Foy, R., Mouery, B. L., Whitaker, R. H., Corno, A., Spanos, C., Ly, T., Cook, J. G., & Saurin, A. T. (2022) · The EMBO Journal · doi:10.15252/embj.2021108599 · Cited by 142
Xiang, X., Fu, Y., Zhao, K., Miao, R., Zhang, X., Ma, X., Liu, C., Zhang, N., & Qu, K. (2021) · Theranostics · doi:10.7150/thno.55672 · Cited by 124
The Paradoxical Role of Cellular Senescence in Cancer
Yang, J., Liu, M., Hong, D., Zeng, M., & Zhang, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.722205 · Cited by 125
Targeting senescence as an anticancer therapy
Bousset, L., & Gil, J. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13312 · Cited by 113
Self-citationChromatin basis of the senescence-associated secretory phenotype
Hao, X., Wang, C., & Zhang, R. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.12.003 · Cited by 94
Crozier, L., Foy, R., Adib, R., Kar, A., Holt, J. A., Pareri, A. U., Valverde, J. M., Diazgranados, R. R., Weston, W. A., Wilson, R., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.10.016 · Cited by 108
mTOR Activity and Autophagy in Senescent Cells, a Complex Partnership
Cayo, Á., Segovia, R., Venturini, W., Moore‐Carrasco, R., Valenzuela, C. A., & Brown, N. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158149 · Cited by 96
Igarashi, K., Nishizawa, H., Saiki, Y., & Matsumoto, M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101032 · Cited by 89
Cell cycle dysregulation in cancer
Glaviano, A., Singh, S. K., Lee, E. H. C., Okina, E., Lam, H. Y., Carbone, D., Reddy, E. P., O’Connor, M. J., Koff, A., Singh, G., et al. (2024) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100030 · Cited by 98
Glaviano, A., Wander, S. A., Baird, R. D., Yap, K. C.-Y., Lam, H. Y., Toi, M., Carbone, D., Geoerger, B., Serra, V., Jones, R. H., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101103 · Cited by 87
Lu, C., Lv, Y., Kou, G., Liu, Y., Liu, Y., Chen, Y., Wu, X., Yang, F., Luo, J., & Yang, X. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.113993 · Cited by 75
Oncogenic signals prime cancer cells for toxic cell overgrowth during a G1 cell cycle arrest
Foy, R., Crozier, L., Pareri, A. U., Valverde, J. M., Park, B. H., Ly, T., & Saurin, A. T. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.10.020 · Cited by 75
Xue, H., Zhao, B., Zhou, W., Liu, H., Fukumoto, T., Gabrilovich, D. I., & Zhang, R. (2020) · iScience · doi:10.1016/j.isci.2020.102016 · Cited by 64
The Jekyll and Hyde of Cellular Senescence in Cancer
Demirci, D., Dayanc, B., Mazi, F. A., & Şentürk, Ş. (2021) · Cells · doi:10.3390/cells10020208 · Cited by 62
Xiong, J., Dong, L., Lv, Q., Yin, Y., Zhao, J., Ke, Y., Wang, S., Zhang, W., & Wu, M. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1772 · Cited by 58
Senolytics: Eliminating Senescent Cells and Alleviating Intervertebral Disc Degeneration
Wu, Y., Shen, S., Shi, Y., Tian, N., Zhou, Y., & Zhang, X. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.823945 · Cited by 53
Luo, J., Sun, T., Liu, Z., Liu, Y., Liu, J., Wang, S., Shi, X., & Zhou, H. (2025) · International Journal of Oral Science · doi:10.1038/s41368-025-00380-w · Cited by 61
Cancer Response to Therapy-Induced Senescence: A Matter of Dose and Timing
Mongiardi, M. P., Pellegrini, M., Pallini, R., Levi, A., & Falchetti, M. L. (2021) · Cancers · doi:10.3390/cancers13030484 · Cited by 49
Targeting CDK4/6 for Anticancer Therapy
Qi, J., & Ouyang, Z. (2022) · Biomedicines · doi:10.3390/biomedicines10030685 · Cited by 49
Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer
Zhu, X., Fu, Z., Dutchak, K., Arabzadeh, A., Milette, S., Steinberger, J., Morin, G., Monast, A., Pilon, V., Kong, T., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1749 · Cited by 46
Willobee, B. A., Gaidarski, A. A., Dosch, A. R., Castellanos, J. A., Dai, X., Mehra, S., Messaggio, F., Srinivasan, S., VanSaun, M. N., Nagathihalli, N. S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1043 · Cited by 43
Gleason, C. E., Dickson, M. A., Klein, M. E., Antonescu, C. R., Gularte‐Mérida, R., Benitez, M., Delgado, J. I., Kataru, R. P., Tan, M. W. Y., Bradić, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2378 · Cited by 39
Bontempi, D., Zalay, O. C., Bitterman, D. S., Birkbak, N. J., Shyr, D., Haugg, F., Qian, J. M., Roberts, H. J., Perni, S., Prudente, V., et al. (2025) · The Lancet Digital Health · doi:10.1016/j.landig.2025.03.002 · Cited by 49
Immunomodulatory effects of CDK4/6 inhibitors
Zhang, S., Xu, Q., Sun, W., Zhou, J., & Zhou, J. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188912 · Cited by 34
Palbociclib releases the latent differentiation capacity of neuroblastoma cells
Ferguson, K. M., Gillen, S. L., Chaytor, L., Poon, E., Marcos, D., Gomez, R. L., Woods, L. M., Mykhaylechko, L., Elfari, L. M., Costa, B. M. D., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.08.028 · Cited by 32
Cellular senescence offers distinct immunological vulnerabilities in cancer
Zhou, L., Ma, B., & Ruscetti, M. A. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.11.010 · Cited by 40
Oxidative Stress, Inflammation, and Cellular Senescence in Neuropathic Pain: Mechanistic Crosstalk
Stojanović, B., Bevc, I. M., Stojanovic, M. D., Stojanović, B., Lazarević, T., Spasić, M., Petrovic, M., Stefanovic, I., Marković, M., Nešić, J., et al. (2025) · Antioxidants · doi:10.3390/antiox14101166 · Cited by 39
The Intricate Interplay between Cell Cycle Regulators and Autophagy in Cancer
Ziegler, D. V., Huber, K., & Fajas, L. (2021) · Cancers · doi:10.3390/cancers14010153 · Cited by 34
Rentschler, M., Braumüller, H., Briquez, P. S., & Wieder, T. (2022) · Cancers · doi:10.3390/cancers14061364 · Cited by 34
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer
Ziegler, D. V., Parashar, K., & Fajas, L. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.12.002 · Cited by 32
Senolytics: charting a new course or enhancing existing anti-tumor therapies?
Czajkowski, K., Herbet, M., Murias, M., & Piątkowska‐Chmiel, I. (2024) · Cellular Oncology · doi:10.1007/s13402-024-01018-5 · Cited by 35
Eskiler, G. G., Özkan, A. D., Haciefendi, A., & Bilir, C. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101243 · Cited by 29
Carpintero-Fernández, P., Borghesan, M., Eleftheriadou, O., Pan‐Castillo, B., Fafián‐Labora, J., Mitchell, T. P., Yuste, A., Öğrünç, M., Nightingale, T. D., Mayán, M. D., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04569-3 · Cited by 30
The p21CIP1-CDK4-DREAM axis is a master regulator of genotoxic stress-induced cellular senescence
Schmidt, A., Allmann, S., Schwarzenbach, C., Snyder, P., Chen, J., Nagel, G., Schöneis, A., Rasenberger, B., Beli, P., Loewer, A., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae426 · Cited by 29
Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool
Nakajima, R., Zhao, L., Zhou, Y., Shirasawa, M., Uchida, A., Murakawa, H., Fikriyanti, M., Iwanaga, R., Bradford, A. P., Araki, K., et al. (2023) · Genes · doi:10.3390/genes14020393 · Cited by 32
Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues
Marei, H. E. S., Bedair, K., Hasan, A., Al-Mansoori, L., Gaiba, A., Morrione, A., Cenciarelli, C., & Giordano, A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00931-8 · Cited by 31
Understanding cellular senescence: pathways involved, therapeutics and longevity aiding
Kumar, A., & Thirumurugan, K. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2287929 · Cited by 31
Gallanis, G. T., Sharif, G. M., Schmidt, M. O., Friedland, B., Battina, R., Rahhal, R., Davis, J. W., Khan, I., Wellstein, A., & Riegel, A. T. (2023) · Cancers · doi:10.3390/cancers15061908 · Cited by 25
Kwiatkowski, N., Liang, T., Sha, Z., Collier, P. N., Yang, A., Sathappa, M., Paul, A., Su, L., Zheng, X., Aversa, R., et al. (2025) · Cell Chemical Biology · doi:10.1016/j.chembiol.2025.03.006 · Cited by 23
Magallón‐Lorenz, M., Fernández‐Rodríguez, J., Terribas, E., Creus‐Bachiller, E., Romagosa, C., Estival, A., Sidelnikova, D. P., Salvador, H., Villanueva, A., Blanco, I., et al. (2021) · Human Genetics · doi:10.1007/s00439-021-02296-x · Cited by 23
Wang, X., Shi, W., Wang, X., Lu, J., He, P., Zhang, H., & Chen, X. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01658-w · Cited by 22
Zheng, Y., Wang, L., Wang, J., Zhao, T., & Wang, J. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673271261231213051410 · Cited by 23
Breaking Cancer’s Momentum: CDK4/6 Inhibitors and the Promise of Combination Therapy
Liu, Y., Park, S., & Li, Y. (2025) · Cancers · doi:10.3390/cancers17121941 · Cited by 21
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma
Aliagas, E., Alay, A., Martínez‐Iniesta, M., Hernández-Madrigal, M., Cordero, D., Gausachs, M., Pros, E., Saigí, M., Busacca, S., Sharkley, A. J., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01547-y · Cited by 21
Targeting cellular senescence to combat cancer and ageing
Wang, C., Hao, X., & Zhang, R. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13266 · Cited by 20
Mitochondrial priming and response to BH3 mimetics in “one-two punch” senogenic-senolytic strategies
López, J., Llop‐Hernández, À., Verdura, S., Serrano‐Hervás, E., Martinez‐Balibrea, E., Bosch‐Barrera, J., Teixidor, E., López‐Bonet, E., Martín-Castillo, B., Josep Sardanyés, A., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02379-y · Cited by 20
Kong, P., Yang, X. M., Zhang, Y., Dong, H., Liu, X., Xu, X., Zhang, X., Shi, Y., Hou, M., & Song, B. (2022) · Journal of Oncology · doi:10.1155/2022/2260625 · Cited by 17
RB functions as a key regulator of senescence and tumor suppression
Gao, M., Li, H., & Zhang, J. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.11.004 · Cited by 17
Senescence in cancer: Hallmarks, paradoxes, and therapeutic promise
Hinterleitner, C., Goldberg, H. V., McHugh, D., Barthet, V. J. A., Filliol, A. A., & Lowe, S. W. (2026) · Cell · doi:10.1016/j.cell.2026.03.005 · Cited by 20
Sterile inflammation in liver transplantation
Kahan, R., Cray, P. L., Abraham, N., Gao, Q., Hartwig, M. G., Pollara, J., & Barbas, A. S. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1223224 · Cited by 16
Zhang, Q., Lou, Y., Fang, H., Sun, S., Jin, R., Ji, Y., & Chen, Z. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12438 · Cited by 17
Nadeem, J., Sultana, R., Parveen, A., & Kim, S. Y. (2025) · Cell Biochemistry and Function · doi:10.1002/cbf.70046 · Cited by 19
Jia, Q., Xie, B., Zhao, Z., Huang, L., Wei, G., & Ni, T. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13125 · Cited by 16
Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma
Julve, M., Clark, J. J., & Lythgoe, M. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1828348 · Cited by 17
Influence of tumor microenvironment on the different breast cancer subtypes and applied therapies
Almeida, C. F., Correia‐da‐Silva, G., Teixeira, N. A. A., & Amaral, C. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116178 · Cited by 16
Cancer and aging: A call to action
Braithwaite, D., Anton, S. D., Mohile, S. G., DeGregori, J. V., Gillis, N., Zhou, D., Bloodworth, S., Pahor, M., & Licht, J. D. (2022) · Aging and Cancer · doi:10.1002/aac2.12055 · Cited by 13
Duah, E., Seligson, N. D., Persaud, A. K., Dam, Q., Pabla, N., Rocco, J. W., Li, J., & Poi, M. J. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23556 · Cited by 14
Xiang, M., Gao, Y., Zhou, Y., Wang, M., & Yao, X. (2023) · BMC Cancer · doi:10.1186/s12885-023-11075-y · Cited by 13
Spring, L. M., Scarpetti, L., Medford, A. J., Niemierko, A., Comander, A. H., Mulvey, T. M., Schnipper, L. E., Isakoff, S. J., Moy, B., Wander, S. A., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-024-00708-5 · Cited by 13
Bacca, L. F. G., Brandariz, J., Zacchi, F., Zivi, A., Mateo, J., & Labbé, D. P. (2025) · Gene · doi:10.1016/j.gene.2025.149774 · Cited by 12
Ji, J., Liu, W., Xu, Y., Zhou, X., Lv, M., Feng, J. Q., Lv, J., He, X., Zhang, Z., Xie, M., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1072194 · Cited by 12
Why is PAK4 overexpressed in cancer?
Costa, T. D. F., & Strömblad, S. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106041 · Cited by 12
Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
Sun, C., Talukder, M., Cao, D., & Chen, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.829759 · Cited by 12
Cell cycle exits and U-turns: Quiescence as multiple reversible forms of arrest
Johnson, M. S., & Cook, J. G. (2023) · Faculty Reviews · doi:10.12703/r/12-5 · Cited by 16
Schoenwaelder, N., Salewski, I., Engel, N., Krause, M., Schneider, B., Müller, M. K., Riess, C., Lemcke, H., Skorska, A., Große-Thie, C., et al. (2021) · Cancers · doi:10.3390/cancers13102396 · Cited by 12
Discovery of small molecule degraders for modulating cell cycle
Wang, L., Yang, Z., Li, G., Liu, Y., Ai, C., & Rao, Y. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1027-5 · Cited by 10
De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression
Tangudu, N. K., Buj, R., Wang, H., Wang, J., Cole, A. R., Uboveja, A., Fang, R. S., Amalric, A., Yang, B., Chatoff, A. G., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0450 · Cited by 13
Verhees, F., Demers, I., Legemaate, D., Jacobs, R., Hoeben, A., Kremer, B., & Speel, E. M. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5719 · Cited by 10
Paternot, S., Raspé, E., Meiller, C., Tarabichi, M., Assié, J., Libert, F., Remmelink, M., Bisteau, X., Pauwels, P., Blum, Y., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13351 · Cited by 10
Tatar, C., Avcı, Ç. B., Açıkgöz, E., & Öktem, G. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.09.032 · Cited by 11
Pita, J. M. G., Raspé, E., Coulonval, K., Decaussin‐Petrucci, M., Tarabichi, M., Dom, G., Libert, F., Craciun, L., Andry, G., Wicquart, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1247542 · Cited by 12
Miyamoto, S., Tanaka, T., Hirosuna, K., Nishie, R., Ueda, S., Hashida, S., Terada, S., Konishi, H., Kogata, Y., Taniguchi, K., et al. (2022) · Cancers · doi:10.3390/cancers14122969 · Cited by 10
Zou, Y., Li, Z., Lin, Y., Zheng, Y., Liu, Z., Li, Y., Huang, L., Chen, Z., & Zhu, L. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119168 · Cited by 9
Lin, C.-Y., Yu, C.-J., Liu, C., Chao, T., Huang, C., Tseng, L., & Lai, J. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02881-0 · Cited by 9
Mouery, B. L., Baker, E., Liu, M., Wolff, S. C., Mills, C. A., Fleifel, D., Mulugeta, N., Herring, L. E., & Cook, J. G. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2319574121 · Cited by 9
Albert, V., Bruß, C., Tümen, D., Piendl, G., Weber, F., Dahl, E., Seitz, S., Ortmann, O., Wege, A. K., & Brockhoff, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137475 · Cited by 9
Mayayo‐Peralta, I., Faggion, B., Hoekman, L., Morris, B., Lieftink, C., Goldsbrough, I., Buluwela, L., Siefert, J. C., Post, H., Altelaar, M. A. F., et al. (2021) · Cancers · doi:10.3390/cancers13246314 · Cited by 8
Matsunaga, T., Roesel, M. J., Schroeter, A., Xiao, Y., Zhou, H., & Tullius, S. G. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001019 · Cited by 8
Antioxidant Senotherapy by Natural Compounds: A Beneficial Partner in Cancer Treatment
Aleksandrova, Y. R., & Неганова, М. Е. (2025) · Antioxidants · doi:10.3390/antiox14020199 · Cited by 8
Stem cell-based targeted therapy in pancreatic cancer: Current approaches and future prospects
Mahadiuzzaman, A. S. M., Opo, F. A. D. M., & Alkarim, S. (2024) · Tissue and Cell · doi:10.1016/j.tice.2024.102449 · Cited by 7
Jin, X., Spöttl, G., Maurer, J., Nölting, S., & Auernhammer, C. J. (2021) · Cancers · doi:10.3390/cancers13061485 · Cited by 8
Cellular senescence in colorectal cancer: its occurrence, effect and therapy
Liang, Y., Wang, M., Wang, X., Yang, Z., Wang, S., Li, F., Su, L., & Yang, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1580951 · Cited by 5
Case series of metastatic breast cancer patients with visceral crisis treated with CDK4/6 inhibitors
Meegdes, M., van der Velde, M. G. A. M., Geurts, S. M. E., van Kats, M. A. C. E., Dercksen, M. W., & Tjan‐Heijnen, V. C. G. (2023) · Journal of Chemotherapy · doi:10.1080/1120009x.2023.2279831 · Cited by 5
The deleterious effects of CDK4/6 inhibition on renal recovery post-acute kidney injury
Zhou, S., Peng, R., Shen, Y., Huang, L., Han, S., Wang, J., & Guo, J. Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-79663-x · Cited by 5
Sutanto, H., Ahkami, A., Fetarayani, D., & Romadhon, P. Z. (2025) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-025-00333-8 · Cited by 7
In vivo senescence imaging nanoprobe targets the associated reactive oxygen species
Lee, S. K., Han, M. S., & Tung, C. (2023) · Nanoscale · doi:10.1039/d3nr04083f · Cited by 5
Brandariz, J., de Llobet, L., Esquefa, V., Aguilar, D., Salca, A., Arce-Gallego, S., Cresta Morgado, P., Sole, A., Agundez, L., Mir, G., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0903 · Cited by 5
The Dual Effects of CDK4/6 Inhibitors on Tumor Immunity
Si, Y., Li, H., & Shi, Y. (2025) · Cancers · doi:10.3390/cancers17243997 · Cited by 4
Cellular senescence in reproduction: a two-edged sword
Pretto, L., Nabinger, E., Filippi‐Chiela, E. C., & Fraga, L. R. (2024) · Biology of Reproduction · doi:10.1093/biolre/ioae025 · Cited by 5
Nagel, S., Fischer, A., Bens, S., Hauer, V., Pommerenke, C., Uphoff, C. C., Zaborski, M., Siebert, R., & Quentmeier, H. (2023) · Leukemia Research · doi:10.1016/j.leukres.2023.107377 · Cited by 4
Costa, A., Forte, I. M., Pentimalli, F., Iannuzzi, C. A., Alfano, L., Capone, F., Camerlingo, R., Calabrese, A., von Arx, C., Dominguez-Benot, R., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1418951 · Cited by 5
A SAR and QSAR study on cyclin dependent kinase 4 inhibitors using machine learning methods
Pang, X., Zhao, Y., Guo, L., Liu, J., & Yan, A. (2023) · Digital Discovery · doi:10.1039/d2dd00143h · Cited by 5
Metadata
- Authors
- Wagner, V., & Gil, J.
- Affiliations
- MRC London Institute of Medical Sciences (GB)
- Corresponding author
- Gil, Jesús
- Venue
- Oncogene
- Published
- 2020-06-15
- Volume
- 39
- Issue
- 29
- Pages
- 5165-5176
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- PMC
- PMC7610384
- OpenAlex
- W3034793718
- Cited by
- 148
- References
- 107
- Citations by year
- 2026: 25 · 2025: 30 · 2024: 22 · 2023: 28 · 2022: 20 · 2021: 20 · 2020: 3
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Cancer Research UK (C15075/A28647)
- RCUK | Medical Research Council (MC_U120085810)
- German Cancer Aid Mildred- Scheel-Postdoc Program
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- cellular senescence, CDK4/6 inhibitors, retinoblastoma protein, E2F transcription factors, cell cycle arrest, senescence-associated secretome, senolytics, combination therapy, immune checkpoint inhibitors, MEK inhibitors, PI3K inhibitors, ER-positive HER2-negative breast cancer, antiestrogens, tumor microenvironment
- MeSH terms
- Female, Humans, Male, Cellular Senescence, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
